




Incorporating Novel CV Risk Reduction Strategies for my High-risk Patients: Where IPE fits into my practice

SATURDAY, MAY 28, 2022

12:05-12:25 pm EDT



VINEETA AHOOJA

MD, FACC, FASE
Toronto, ON



ANIL GUPTA

MD, FRCPC
Staff Cardiologist, Trillium Health Partners (THP)
Lead, Cardiac Diagnostics and Cardiac Rehabilitation (THP)
Lecturer, University of Toronto
Investigator, Institute for Better Health (THP)
Research Director, One Heart Care Ventures
Toronto, ON

Learning objectives:

- Define clinical considerations for identifying patients at high risk for CV events
- Describe optimizing CV risk management for statin-treated patients with CV risk
- Discuss practice changes in recent years incorporating icosapent ethyl (IPE) for patients with high CV risk based on evidence and guideline recommendations

This Corridor Consult is available **LIVE** for the **VIRTUAL** audience and **ON-DEMAND** for all delegates after the congress

Visit cardiovasupdate.ca to register for the hybrid congress